COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #48 of 231
5/28 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Chatterjee et al., Indian J. Med. Res., June 20, 2020, doi:10.4103/ijmr.IJMR_2234_20 (Peer Reviewed)
Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19
Source   PDF   Share   Tweet
4+ doses of HCQ associated with a significant decline in the odds of getting infected, dose-response relationship exists.

Chatterjee et al., 5/28/2020, retrospective, India, South Asia, peer-reviewed, survey, 11 authors.
risk of COVID-19 case, 66.8% lower, RR 0.33, p < 0.001, treatment 12 of 68 (17.6%), control 206 of 387 (53.2%), full course vs. unused.
Details of all 231 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit